Oral versus intravenous iron for anemia in pregnancy: a cost-effectiveness analysis.
| Autor: | Dazelle WDH, Ebner MK; The George Washington University School of Medicine and Health Sciences, Washington, United States., Potarazu S; The George Washington University School of Medicine and Health Sciences, Washington, United States., Kazma J; George Washington University Hosptial, Washington DC, United States., Ahmadzia H; OB/Gyn, George Washington University Medical Faculty Associates, Washington, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | American journal of perinatology [Am J Perinatol] 2024 Jan 30. Date of Electronic Publication: 2024 Jan 30. |
| DOI: | 10.1055/a-2257-3586 |
| Abstrakt: | Our findings suggest that treating antepartum anemia with currently available iron therapies would result in significant cost-savings and reductions in adverse outcomes associated with anemia in this context. Ferric carboxymaltose likely confers the greatest overall benefit among competing options. This conclusion is robust to uncertainty, even when the cost these therapies is significantly higher than is demonstrated in the literature. Competing Interests: The authors declare that they have no conflict of interest. (Thieme. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|